Related Experiment Video
Updated: Jun 16, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis,
Yutaka Kimura1, Hirohisa Machida, Kazumasa Fujitani
1Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), NTT West Osaka Hospital, Japan.
Background:
The standard therapy for gastric cancer with peritoneal metastasis has remained unclear.
Purpose:
This prospective feasibility study was aimed to investigate the efficacy and safety of S-1 plus paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis able to take oral feeding.
Patients And Methods:
Seven patients were enrolled in this study. Paclitaxel 50mg/m2 was administered on days 1 and 8. S-1 was administered orally at 40 mg/m2 bid for 14 consecutive days, followed by a 1-week rest. Overall survival, the response rate and safety were examined for efficacy and tolerability.
Results:
The median survival time was 310 days. The response rate in five patients was 80. 0%. Grade 3 toxicity was observed in two patients. Combination chemotherapy of weekly paclitaxel and S-1 demonstrated efficacy and tolerable toxicity. This regimen will be one of the initial treatment options for unresectable or metastatic gastric cancer with peritoneal metastasis.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
